ErbB3 is a transmembrane growth factor receptor that has been implicated in the pathogenesis of human cancer. After finding that a truncated form of ErbB3 was present and upregulated in metastatic prostate cancer cells in lymph nodes and bone, we explored the pathophysiological functions of this unusual form of ErbB3 in the context of mouse calvaria as well as osteoblasts in vitro and the femur microenvironment in vivo. Here we demonstrate that prostate cancer cells expressed an alternatively spliced transcript that encodes a 45-kDa glycosylated protein (p45-sErbB3). The recombinant p45-sErbB3 purified from conditioned medium stimulated calvarial bone formation and induced osteoblast differentiation. Overexpression of p45-sErbB3 in the osteolytic prostate cancer cell line PC-3 converted its phenotype from bone lysing to bone forming upon injection into the femurs of immunodeficient mice. Further, we detected sErbB3 in plasma samples from patients with castration-resistant prostate cancer with bone metastasis. These observations establish that p45-sErbB3 is a structurally and functionally unique gene product of ErbB3 and suggest that p45-sErbB3 is likely one of the factors involved in the osteoblastic bone metastases of prostate cancer.
Introduction
ErbB3 is a member of transmembrane growth factor receptors, which are often overexpressed in tumor cells. In the presence of ligands, such as heregulin, ErbB3 forms heterodimers with ErbB2 or any other epidermal growth factor receptor to activate intracellular signaling events that promote cell proliferation, survival and migration (Alimandi et al., 1995; Hellyer et al., 2001) . Upregulation of ErbB3 has been observed in several carcinoma specimens and cancer cell lines (Kraus et al., 1989; Naidu et al., 1998) . High levels of ErbB3 protein expression have been linked with shorter survival among patients with advanced non-small cell lung carcinoma (Yi et al., 1997) .
Although ErbB3 has always been considered a transmembrane protein with an apparent molecular mass of 180 kDa, we previously detected a truncated form of ErbB3, with a molecular mass of 45 kDa, in pooled bone marrow supernatant samples from men with prostate cancer that had metastasized to the bone (Vakar-Lopez et al., 2004) . Our subsequent examination of the expression of this truncated form of ErbB3 (previously named MDA-BF-1) during prostate cancer progression showed that it was expressed in metastatic prostate cancer cells in lymph nodes and bone but not in the primary prostate cancer (Vakar-Lopez et al., 2004) . These findings raised the possibility that this truncated form of ErbB3 may be involved in prostate cancer progression.
Prostate cancer bone metastases are characterized by their ability to induce osteoblastic lesions and localized bone formation (Berruti et al., 2000) . The observation of bone formation (as opposed to bone lysis) in prostate cancer bone metastases has led us to hypothesize that prostate cancer cells produce factors that promote the growth and differentiation of osteoblasts, and that bidirectional interactions between prostate cancer cells and bone are critical for the preferential metastasis of prostate cancer to bone (Logothetis and Lin, 2005) . Our previous study showed that p45-sErbB3 stimulated mouse calvaria to secrete osteonectin (Chen et al., 2007) . The increase in the osteonectin secretion from bone led to the increase in the invasiveness of PC-3 cells as measured in a Boyden chamber invasion assay. These observations indicate that p45-sErbB3 can increase PCa invasiveness indirectly through its effect on bone. However, it is not clear whether prostate cancer cells express the transcript that encodes the 45-kDa form of ErbB3 and the protein affects the growth or differentiation of osteoblasts.
In this study, we investigated the effect of p45-sErbB3 on osteoblasts. Our results indicate that prostate cancer cells express one of the two known alternatively spliced ErbB3 isoforms that lacks the transmembrane domain and C-terminal sequence. We show that the derived soluble p45-sErbB3 glycoprotein promotes the growth and differentiation of osteoblasts in vitro and stimulates bone formation in vivo.
Results
Prostate cancer cells produce an alternatively spliced transcript of ErbB3 The transcript for the full-length 180-kDa ErbB3 is encoded by 28 exons of the ErbB3 gene. Our search of the GenBank database for alternatively spliced transcripts of ErbB3 found three mRNA sequences (accession numbers BC002706, BT007226 and U88358). Analysis of these sequences revealed that the BC002706/ BT007226 transcript results from splicing of exon 8 to exon 26 of ErbB3, whereas the U88358 transcript results from intron 8 retention (Figure 1a ). Both the deduced isoforms contain N-terminal signal peptide sequences and partial extracellular domains of ErbB3 with a calculated molecular weight of about 35 kDa, but lack the transmembrane or cytoplasmic domains. Next, we analysed the presence of these transcripts in three prostate cancer cell lines-LNCaP, PC-3 and DU145-by reverse transcription polymerase chain reaction (RT-PCR). We found that all three cell lines expressed small but readily detectable amounts of the U88358 transcript (Figure 1b) but not the BC002706/ BT007226 transcript (data not shown). Thus, prostate cancer cells only express the alternatively spliced ErbB3 transcript that retains intron 8 sequence.
The alternatively spliced transcript produces a secreted glycoprotein In order to isolate the soluble p45-sErbB3 for functional characterization of this protein, we generated both and p180-ErbB3. p180-ErbB3 contains four ligand-binding subdomains (I-IV), a single transmembrane (TM) domain and a cytoplasmic domain. Two alternatively spliced sequences from GenBank may encode p45-sErbB3. One transcript (BC002706 or BT007226) has exon 8 to exon 26 splicing and the other (U88358) has intron 8 retention. Translation of the latter transcript is expected to terminate after exon 8 due to a shift in the open reading frame. (b) Prostate cancer cells produce an alternatively spliced ErbB3 transcript. RT-PCR of the RNA from the three prostate cancer cell lines, using primers specific to the exon 6-exon 7 junction and to intron 8, generated a 326-bp transcript-the predicted size from U88358 (left). This amplicon hybridized with an oligonucleotide probe specific to exon 8 (right), confirming that it is an alternatively spliced ErbB3 transcript. (c) The alternatively spliced transcript encodes a secreted protein. LNCaP, PC-3 and DU145 prostate cancer cells were infected with Ad-p45 (p45) or with Ad-luciferase (C) for 48 h, after which the conditioned medium (CM) and cell lysates (Lys) were analysed for the expression of p45-sErbB3 by western blotting. (d) p45-sErbB3 is a glycoprotein. CM from Ad-p45 infected cells was treated ( þ ) or not treated (À) with peptidyl N-glycosidase F (PNGase) for 1 h and analysed by western blotting. (Figure 1d ), the mass that was predicted from the cDNA sequence. These findings suggest that the secreted p45-sErbB3 is a glycosylated protein.
p45-sErbB3 stimulates osteoblast activities in vitro As the soluble ErbB3 was initially identified in the bone marrow of prostate cancer patients with bone metastasis (Vakar-Lopez et al., 2004) , the question arises whether this protein has any function on osteoblasts. In order to determine whether p45-sErbB3 participates in regulating osteoblast activity in vitro, we used the affinity-purified recombinant p45-sErbB3 protein ( Figure 2a ) to test its effects on growth of calvaria bone in organ cultures. Calvaria were obtained from postnatal day 2 to day 4 mice and incubated with various amounts of recombinant p45-sErbB3 for 4 days. p45-sErbB3 incubation resulted in dose-dependent increases in calvaria bone thickness ( Figure 2a ). Quantitative analysis of the effect of p45-sErbB3 on bone formation showed that treatment of calvaria with 100 ng/ml p45-sErbB3 induced increases in osteoblast numbers, new bone area and total bone area (Figure 2a ), indicating that p45-sErbB3 has a bioactivity to stimulate bone formation in vitro. Similar results were obtained with recombinant p45-sErbB3 protein expressed from either mammalian cells or insect cells. For subsequent experiments, we used 100 ng/ml p45-sErbB3 as its effects on osteoblasts were reproducible and relatively consistent. To see whether the increase in bone formation resulted from stimulation of osteoblast proliferation, primary mouse osteoblasts (PMOs) were isolated from neonatal calvaria and incubated with or without various concentrations of recombinant p45-sErbB3 expressed from Sf9 insect cells or PC-3 mammalian cells. The recombinant p45-sErbB3 protein that was expressed from Sf9 insect cells induced a small but reproducible and statistically significant increase in the proliferation of PMOs as measured by 3 H-thymidine incorporation and cell counts ( Figure 2b ). We found that p45-sErbB3 elicited a detectable response with as low as 25 ng/ml of p45-sErbB3 recombinant protein expressed from Sf9 cells (Figure 2b ). Similar results were obtained by using recombinant p45-sErbB3 protein expressed from mammalian cells (Figure 2c ), suggesting that the increase in cell proliferation is most likely due to the recombinant p45-sErbB3 protein. In addition, infection of PMOs with recombinant p45-sErbB3 virus (Ad-p45; with Ad-luciferase used as a control) led to similar results in cell proliferation ( Figure 2c ). These observations indicate that p45-sErbB3 promotes a moderate increase in osteoblast proliferation.
We further tested whether p45-sErbB3 affects osteoblast differentiation. Incubating PMOs with p45-sErbB3 in osteoblast differentiation medium led to significant increases in alkaline phosphatase activity, a marker of osteoblast differentiation, relative to untreated controls ( Figure 2d ). von Kossa staining also showed that p45-sErbB3 treatment led to an increase in the numbers of mineralized bone-like nodules formed by PMOs (Figure 2e ). Together, these results indicate that p45-sErbB3 also promotes osteoblast differentiation.
p45-sErbB3 promotes bone formation in vivo To assess the effect of p45-sErbB3 on bone formation in vivo, we used the prostate cancer cell line PC-3, which typically produces osteolytic lesions upon injection into mouse bone, to test whether overexpression of p45-sErbB3 in this cell line would promote bone formation. For these experiments, we transfected PC-3 cells with a FLAG-tagged p45-sErbB3 expression construct or a control (neo) vector and generated stable transfectants by antibiotic selection. As expected, the transfectant PC/ p45-sErbB3 expressed and secreted the recombinant protein into the conditioned medium ( Figure 3a) . However, overexpression of p45-sErbB3 affected neither PC-3 cell proliferation in vitro (Figure 3b ) nor PC-3 growth in vivo after cells were injected subcutaneously in the flanks of nude mice ( Figure 3c ).
Next, we performed in an intrabone assay in which PC/p45-sErbB3 or control PC/neo cells were injected into the femurs of male severe combined immunodeficiency disease (SCID) mice, and the corresponding bone structure was examined over the ensuing 4 weeks. In agreement with previous observations by others (Soos et al., 1996; Wu et al., 1998; Corey et al., 2002) , PC/neo cells produced osteolytic responses at the injection sites in all of the mice examined (Figure 4a ). The extent of bone lysis correlated with increased numbers of osteoclasts in the lesions (Figure 4a , arrows, Â 100). In contrast, one of three mice injected with PC/p45-sErbB3 cells did not show bone lysis; rather, new bone formation and activated osteoblasts were evident, surrounding the tumor (Figure 4a , arrowheads, Â 100). Immunohistochemical staining for p45-sErbB3 was positive for the bone-forming tumor (Figure 4a , T) and negative for the two osteolytic tumors (data not shown). The lack of staining in the osteolytic tumors may have resulted from the presence of p45-sErbB3-negative cells in the mixed transfectants used for injection into SCID mice.
Finally, we cloned and selected PC/p45-sErbB3 subclines (clones no. 16, no.18, no. 19 ) that expressed the greatest amounts of p45-sErbB3 and injected those cells into the right femurs of five mice. Histologic analysis of the injected femurs showed bone-forming responses (Figure 4b , new bone B*) in the tumorinvaded area (Figure 4b , T) in all five mice with tumors p45-sErbB3 promotes bone formation S-H Lin et al in the bone. Although the number of mice is small, these results suggest that the expression of p45-sErbB3 converted PC-3 cells from a bone-lysing to a boneforming phenotype in bone, and support our observations from the in vitro studies that p45-sErbB3 stimulates osteoblast activity and promotes bone formation.
Levels of sErbB3 in the conditioned medium of cell lines and in human plasma samples We developed an enzyme-linked immunosorbent assay (ELISA) assay to measure the levels of sErbB3 in the conditioned medium of prostate cancer cell lines and in the plasma of men with progressive prostate cancer with bone metastasis. The sensitivity of the ELISA assay is p45-sErbB3 promotes bone formation S-H Lin et al 0.2-0.5 ng/ml. sErbB3 levels were very low in the conditioned medium of prostate cancer cell lines. However, sErbB3 became detectable after a 20-fold concentration of the conditioned media by a Centricon concentrator. The levels of sErbB3 in the LNCaP, PC-3 and DU145 conditioned medium were 1.1, 0.4 and 8 ng per 10 6 cells (or 0.11, 0.04 and 0.8 ng/ml), respectively ( Figure 5a ). The level of sErbB3 in the conditioned medium was 0.4 ng per 10 6 cells (or 0.04 ng/ml) in the control PC-3/neo cells, and between 4 and 5.5 ng per 10 6 cells (or 0.4-0.55 ng/ml) in the PC/p45sErbB3 clones no. 16, no. 18, and no. 19 (Figure 5b ), which were used in the in vivo bone-forming assays in Figure 4b .
We also measured sErbB3 in plasma samples from 50 men with progressive castration-resistant prostate cancer with bone metastases. We found that the levels of sErbB3 in the plasma was between 0.4 and 12 ng/ml (Figure 5c ). There was great heterogeneity in the levels of sErbB3 in the plasma from these patients, likely due to the fact that prostate cancer bone metastasis is a heterogeneous disease (Shah et al., 2004) . Among these patient plasma samples, 12 (24%) had sErbB3 levels higher than 1 ng/ml and 20 (40%), between 0.5 and 1.0 ng/ml (Figure 5c ). Together, our measurements of sErbB3 expressed in the transfected PC-3 cell lines and the plasma from prostate cancer patients with bone metastasis indicate that the levels of sErbB3 expressed in these cell lines and in human plasma specimens are comparable, that is, all within the ng per ml range.
Discussion
We demonstrated here that prostate cancer cells express an alternatively spliced transcript of ErbB3 that encodes a secreted form of ErbB3, p45-sErbB3. The p45-sErbB3 protein did not have an autocrine effect on prostate cancer cells, but it stimulated osteoblast activity and bone formation both in vitro and in vivo. Further, we detected sErbB3 in plasma samples from patients with castration-resistant prostate cancer with bone metastasis. Because a hallmark of bone metastasis from prostate cancer is the bone-forming phenotype, our findings raise the interesting possibility that p45-sErbB3 is one of such factors that mediate the bone-forming activity induced by prostate cancer cells.
We have measured the levels of sErbB3 in the conditioned medium of PC/p45-sErbB3 cell lines and in the plasma of men with castration-resistant prostate cancer with bone metastasis. We found that the levels of sErbB3 are within ng per ml range in both cell lines and Figure 2 p45-sErbB3 stimulates bone formation and osteoblast activity in vitro. (a) Recombinant p45-sErbB3 from baculovirusinfected Sf9 cells was purified by metal affinity chromatography. Recombinant p45-sErbB3 stimulates new bone formation in a mouse calvarial culture assay. Neonatal mouse calvaria was treated ( þ ) or not treated (À) with the indicated amounts of recombinant p45-sErbB3 for 4 days. Histologic analysis of the calvaria showed increased thickness in the calvaria that had been treated with p45-sErbB3 but not in the corresponding controls. Increases in osteoblast numbers, total bone area and new bone area in the calvaria treated with p45-sErbB3 (100 ng/ml) relative to those in controls. Error bars represent standard deviation; asterisk (*) denotes significant difference at Po0.001. (b) Effect of recombinant p45-sErbB3 from Sf9 cells on osteoblast proliferation. Primary mouse osteoblasts (PMOs) isolated from neonatal mouse calvaria were treated or not treated with various concentrations of purified p45-sErbB3 protein. Asterisk (*) denotes significant difference at Po0.05. (c) Effect of recombinant p45-sErbB3 from mammalian cells on osteoblast proliferation. Recombinant p45-sErbB3, purified from p45-sErbB3 adenovirus-infected PC-3 cells, or recombinant p45-sErbB3 adenovirus (Ad-p45) at various multiplicities of infection (MOI), was used to treat PMOs isolated from neonatal mouse calvaria. Ad-luciferase was used as a control. Asterisk (*) denotes significant difference at Po0.05. (d) Alkaline phosphatase activity in PMO cultures not treated (control) or treated with p45-sErbB3 (100 ng/ml) in differentiation medium for 15 days. Results are expressed as means; error bars are s.d.; Asterisk (*) denotes significant difference at Po0.05. (e) Formation of bone-like nodules in PMO cultures that were either not treated (control) or treated with p45-sErbB3 (100 ng/ml) for 15 days in differentiation medium, followed by von Kossa staining. p45-sErbB3 promotes bone formation S-H Lin et al human plasma. Due to dilution in the circulation, we estimate that the local concentration of the paracrine factor p45-sErbB3 within the metastatic lesions in bone should be much higher than that measured in the bone marrow or blood. Similarly, the local concentrations of p45-sErbB3 in the mouse femur injected with PC/p45-sErbB3 cells are expected to be much higher than those measured in the conditioned media in vitro. In our in vitro assay, examining the effect of recombinant sErbB3 on mouse calvarial bone growth and PMO Figure 4 p45-sErbB3 induces a bone-forming phenotype in the mouse femurs. (a) PC/neo or PC/p45-sErbB3 cells were injected into the distal ends of the right femurs of 12-week-old male CB.17 severe combined immunodeficiency disease (SCID) mice; left femurs were injected with saline as a control. Severe osteolytic effects (circle) were seen in mouse femurs at 4 weeks after injection of PC/neo cells. Histologic analysis of lesions induced by intrafemoral injection of PC/neo cells at 6 weeks showed a large tumor (T) with severe bone lysis ( Â 40) and osteoclasts (arrows) at the area invaded by tumor ( Â 100). However, no bone lysis (circle) was seen in femurs injected with PC/p45-sErbB3 cells. Histologic analysis of lesions induced by PC/p45-sErbB3 cells revealed the appearance of new bone surrounding the tumor (T; Â 40) and activated osteoblasts (arrowheads) within the woven bone ( Â 100). (b) Histologic analysis of femur lesions induced by the selective PC/p45-sErbB3 clonal cell lines. The newly formed bone (B*) in the tumor (T)-invaded area has features of 'woven bone' that contrast with the appearance of normal bone (b), in which collagen fibers are arranged in lamellae. The dark-staining cells are normal bone marrow cells.
p45-sErbB3 promotes bone formation S-H Lin et al
responses, we found that a detectable bone-forming response can be obtained with 25 ng/ml of p45-sErbB3 recombinant protein. Thus, the concentrations of p45-sErbB3 used in the in vitro calvarial and osteoblast studies are comparable as they are all within the range of sErbB3 detected in human plasma. We have explored the clinical relevance of sErbB3 in a parallel study (Lin et al., 2008) . We investigated whether sErbB3 may participate in the progression of prostate cancer in bone by analysing the levels of sErbB3 in a series of clinical samples from patient bone marrow with the corresponding patient clinical history. ELISA were performed on marrow samples from 108 men (34 with androgen-dependent disease, 30 with androgen-independent disease but negative bone scan and 44 with AI disease and positive bone scan); sequential marrow from 5 men during treatment; plasma from 52 men before and after one course of docetaxel treatment; and plasma from 95 men aged 70 or more with no evidence of prostate cancer. We found that the levels of sErbB3 in the bone marrow was between 0 (undetectable) and 15 ng/ml. As expected, prostate cancer bone metastasis is a heterogeneous disease and there is great heterogeneity in the levels of sErbB3 in the bone marrow and plasma from these patients. However, a subgroup of patients showed high levels of sErbB3, which seems to correlate with metastasis-free progression. This finding suggests that sErbB3 may participate in the progression of prostate cancer in bone.
Using immunohistochemical analysis, we previously observed that 32% of specimens from men with prostate cancer with lymph node metastases, and 42% of specimens from men with prostate cancer with bone metastases expressed the truncated sErbB3 (Vakar-Lopez et al., 2004) . These findings suggest that an as-yet unknown regulatory mechanism controls the alternative splicing of ErbB3 gene transcripts in these metastatic prostate cancer cells and that aberrant regulation of ErbB3 splicing is likely involved in prostate cancer progression.
In other studies, we showed that recombinant p45-sErbB3 can bind to the plasma membranes of cells of osteoblastic lineage (for example, Saos-2, C2C12) but not to those of PC-3 cells or the human embryonic kidney cell line 293 (Liang et al., 2005) , suggesting that p45-sErbB3 is a ligand for a cell-surface receptor on osteoblasts. The identity of the p45-sErbB3 receptor remains to be determined. LNCaP, PC-3 or DU145 cells grown to confluence on 10-cm tissue culture plates was concentrated 20-fold using a Centricon concentrator. Enzyme-linked immunosorbent assay (ELISA) was performed using 100 ml each of the concentrated conditioned medium. The data were expressed as ng per ml of original conditioned medium. (b) Conditioned medium from PC/neo and PC/p45-sErbB3 clones no. 16, no. 18, no. 19 was concentrated 20-fold and the concentration of sErbB3 measured by ELISA. The data were expressed as ng per ml of original conditioned medium. (c) The concentrations of sErbB3 in the plasma samples from 50 men with progressive castration-resistant prostate cancer with bone metastasis were measured by ELISA. The samples are ordered from the lowest to highest sErbB3 levels from left to right on the x axis. Bars a-f represent samples with sErbB3 concentrations higher than 3 ng/ml (3.9 ± 0.3, 5.1 ± 0.2, 7.5 ± 1.2, 9.1 ± 3.0, 11.7 ± 2.5 and 11.8 ± 2.7, respectively).
Previous studies have implicated several known bone growth factors, including bone morphogenetic proteins, platelet-derived growth factor, fibroblast growth factor, vascular endothelial growth factor, Wnt, tumor growth factor-b and endothelin-1 may be involved in formation of osteoblastic metastases in prostate cancer (Logothetis and Lin, 2005) . By contrast, p45-sErbB3 was identified by a comparative analysis of the human bone marrow proteome from men with or without bone metastasis (Vakar-Lopez et al., 2004) . We propose that prostate cancer cells, by producing bone stimulatory factors such as p45-sErbB3, stimulate osteoblast proliferation and differentiation and that the osteoblasts in turn stimulate prostate cancer cell growth in the bone microenvironment. Consistent with this hypothesis, we previously used gene array analysis and observed that p45-sErbB3 upregulated several genes in mouse calvaria (Chen et al., 2007) . One of the genes was osteonectin and we demonstrated that osteonectin induced invasiveness of prostate cancer cells, including PC-3 and C4-2B. Thus through its effects on bone, p45-sErbB3 was able to indirectly increase the invasiveness of prostate cancer cells in bone (Chen et al., 2007) . It is likely that other factors that are implicated in osteoblastic bone metastasis of prostate cancer also play a similar role in the bidirectional interactions between prostate cancer cells and bone. The establishment of this positive feedback loop may be an important step in the progression of prostate cancer in bone (Logothetis and Lin, 2005; Choueiri et al., 2006; Chen et al., 2007) . Collectively, these factors represent potential targets for the development of future biomarkers and therapies.
Bone metastasis is a lethal form of prostate cancer and presents considerable challenges for treatment. Interfering with the interactions between prostate cancer cells and aspects of the bone microenvironment may hold the key to preventing the development of bone metastases. The bone stimulatory property of p45-sErbB3 suggests that this factor is involved in the osteoblastic bone metastasis of prostate cancer and that p45-sErbB3 may be a candidate for development as a target in the treatment or prevention of prostate cancer bone metastasis.
Materials and methods
RT-PCR for p45-sErbB3 message RNA was isolated from prostate cancer cell lines LNCaP, PC-3 and DU145 (American Type Culture Collection, Manassas, VA, USA) by TRIzol extraction (Invitrogen, Carlsbad, CA, USA). The RNA samples were treated with DNase I and further purified with the RNeasy kit (Qiagen, Valencia, CA, USA). cDNA synthesis was performed with the First Strand Synthesis kit (Invitrogen). RT-PCR of the transcript U88358 was carried out by the use of primers specific to the exon 6-exon 7 junction (5 0 -GGACACAGACTGCTTTGCCTGC-3 0 ) and intron 8 (5 0 -GCAGGCTCAGAGGAAAGGCTGT-3 0 ); the expected size of the PCR amplicon was 326 bp. Simultaneously, RT-PCR was performed for the transcripts BC002706 and BT007226 with primers specific to the exon 6-exon 7 junction (5 0 -GGACACAGACTGCTTTGCCTGC-3 0 ) and exon 26 (5 0 -GGGCATGTATCCAGATGATGGAC-3 0 ); the predicted sizes of PCR products were 2426 bp from the transcript encoding for 180-kDa form of ErbB3 and 303 bp from alternatively spliced transcript BC002706 or BT007226. For verification of PCR products, oligonucleotide probes specific to exon 8 (5 0 -TGGGCTCAAGATGTGTGAGCCTTG-3 0 ) or intron 8 (5 0 -ACTTCTTACCATCTCCTACCCACC-3 0 ) were used in Southern hybridization.
Generation of recombinant p45-sErbB3 protein cDNA encoding p45-sErbB3 with a histidine 7 -tag at the COOH terminus was obtained by the RT-PCR cloning designed accordingly to the sequence of U88358. The histidine-tagged p45-sErbB3 was expressed in Sf9 insect cells by using a baculoviral expression system (Liang et al., 2005) or in PC-3 cells by using recombinant adenovirus and purified by Ni-NTA agarose affinity chromatography.
Osteoblast growth and differentiation assays Calvaria were excised from 2-to 4-day-old CD1 mice, cut in half along the midline and incubated in BGJb medium (Invitrogen) containing 1% bovine serum albumin (BSA). Half of calvaria was used as a control and the other half was treated for 4 days with various doses of p45-sErbB3. Calvaria were then fixed and decalcified for histological analyses. PMOs were obtained from the neonatal mouse calvaria as described elsewhere (Yang et al., 2001) . For osteoblast proliferation assay, the PMOs were incubated with various concentrations of p45-sErbB3 in a-medium with 0.1% BSA and cultured for 3 days and the cell number was counted by hemacytometer or the cells were pulse labeled with [ 3 H]-thymidine for 1 h and the radioactivity incorporated into the cells determined. For osteoblast differentiation assay, the PMOs were incubated with or without p45-sErbB3 (100 ng/ml) in minimal essential medium plus 2% fetal bovine serum (FBS) for 4 days to allow cells to reach confluence. The medium was then changed to differentiation medium (with 100 mg/ml ascorbic acid, 5 mM b-glycerol phosphate and 2% FBS), with or without p45-sErbB3. Alkaline phosphatase activity in the cell lysates was assessed by using p-nitrophenyl phosphate as a substrate. von Kossa staining to visualize mineralized bone matrix was carried out as described elsewhere (Bhargava et al., 1988) .
Expression of p45-sErbB3 in PC-3 cells and intrafemoral injection The cDNA encoding p45-sErbB3 with a FLAG-tag at the COOH terminus was obtained by PCR cloning into pRSN vector (Low et al., 1991) . PC-3 cells were transfected with plasmid pRSN-p45-sErbB3 and selected with G418 to produce a pool of G418-resistant p45-sErbB3 transfectants (PC/p45-sErbB3). Controls were generated by transfecting PC-3 with the empty pRSN vector (PC/neo). To assess p45-sErbB3 in the conditioned medium from PC/p45-sErbB3 and PC/neo cells, 10 ml of the conditioned medium from 48 h culture of these cells were immunoprecipitated with anti-FLAG-agarose and western blotted with the anti-ErbB3 antibody Ab-10 (LabVision/NeoMarker, Fremont, CA, USA). To assess PC/neo and PC/p45-sErbB3 cell growth in vitro, cells (2 Â 10 5 ) were plated in 6-well plates and counted every 24 h. To assess the effect of p45-sErbB3 on PC-3 cell growth in vivo, PC/neo or PC/p45-sErbB3 cells were injected subcutaneously into the flanks of male nu/nu mice (1 Â 10 6 cells per site Â 12 sites). Tumors were measured with calipers, weekly, after injection.
For the intrabone assays, PC/neo or PC/p45-sErbB3 cells were injected into the distal ends of the right femurs of 12-week-old male CB.17 SCID mice (Harlan Sprague Dawley, p45-sErbB3 promotes bone formation S-H Lin et al Indianapolis, IN, USA; Yang et al., 2001) . The left femurs were injected with saline as a control. The mice were monitored every 2 weeks by radiography and palpation under anesthesia according to animal protocols established and approved by The University of Texas MD Anderson Cancer Center. Animals were killed at 4-6 weeks after injection, and both the tumor-bearing and the sham-injected legs were harvested. The bones were dissected out, fixed in 4% paraformaldehyde at 4 1C, and decalcified in formic acid. For histologic analysis, 4-mm-thick sections were prepared. Immunohistochemical staining of p45-sErbB3 in tumors was performed as described previously (Vakar-Lopez et al., 2004) .
ELISA for sErbB3 in the conditioned medium of cell lines and in human plasma samples Monoclonal antibody against ErbB3 MAB3481 (R&D Systems) was used to capture the soluble ErbB3 from the study samples and a polyclonal antibody, goat anti-ErbB3 antibody (R&D Systems, Minneapolis, MN, USA), was used to detect the protein. Conditioned medium from cell lines was concentrated 20-fold by Centricon centrifugation and 100 ml of the concentrated conditioned medium was used for ELISA. Human plasma samples were used directly for ELISA measurement. Samples were collected according to a protocol approved by the institutional review board of MD Anderson Cancer Center. The ELISA was performed as follows. First, the 96-well plate was coated with 100 ml of the monoclonal antibody MAB3481 (R&D Systems) at a concentration of 4 ug/ml overnight at room temperature. After washing the wells with phosphate-buffered saline (PBS) plus 0.1% Triton X-100 and blocking with PBS containing 1% BSA, 100 ml of the concentrated conditioned medium or human plasma samples was added to each well and the plates incubated at room temperature for 2 h. The samples were removed and the captured sErbB3 protein was detected with a polyclonal goat anti-ErbB3 antibody (1 mg/ml; R&D Systems) followed with horseradish peroxidase-conjugated anti-goat antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and a substrate reagent pack (R&D Systems). Recombinant p45-sErbB3 purified from p45-sErbB3 adenovirus-infected PC-3 cells was used as a standard and was run in parallel in every assay. The standard curve is linear between 0 and 15 ng/ml p45-sErbB3 and the detection sensitivity is around 0.2-0.5 ng/ml.
Abbreviations
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